Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes
- PMID: 15719378
- DOI: 10.1002/jso.20184
Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes
Abstract
Medullary thyroid carcinoma (MTC) is a rare malignancy with several distinctive features that distinguish its management from other thyroid cancers. First, MTC may be sporadic (75% of cases), or may occur as a manifestation of the hereditary syndrome Multiple Endocrine Neoplasia type 2 (MEN 2) (25% of cases). Additionally, while MTC is more difficult to cure than differentiated thyroid cancer and has higher rates of recurrence and mortality, it is usually a slow growing tumor compared with other malignancies. Finally, unlike differentiated thyroid cancer, there is no known effective systemic therapy for MTC. MTC cells do not concentrate radioactive iodine, and MTC does not respond well to external beam radiation or conventional cytotoxic chemotherapy. These distinguishing features should be considered in planning surgical management of MTC.
(c) 2005 Wiley-Liss, Inc.
Similar articles
-
Current approaches to medullary thyroid carcinoma, sporadic and familial.J Surg Oncol. 2006 Dec 15;94(8):737-47. doi: 10.1002/jso.20690. J Surg Oncol. 2006. PMID: 17131404 Review.
-
[Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].Dtsch Med Wochenschr. 2003 Sep 26;128(39):1998-2002. doi: 10.1055/s-2003-42555. Dtsch Med Wochenschr. 2003. PMID: 14508694 German.
-
Medullary thyroid carcinoma: state of the art.G Chir. 2005 Nov-Dec;26(11-12):405-9. G Chir. 2005. PMID: 16472416 Review.
-
[Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].Genetika. 2003 Jun;39(6):847-54. Genetika. 2003. PMID: 12884527 Russian.
-
Medullary thyroid carcinoma.Clin Oncol (R Coll Radiol). 2010 Aug;22(6):475-85. doi: 10.1016/j.clon.2010.05.002. Clin Oncol (R Coll Radiol). 2010. PMID: 20627492 Review.
Cited by
-
Evidence-based approach to the management of sporadic medullary thyroid carcinoma.World J Surg. 2007 May;31(5):946-56. doi: 10.1007/s00268-006-0846-2. World J Surg. 2007. PMID: 17426901 Review.
-
An introduction to managing medullary thyroid cancer.Hered Cancer Clin Pract. 2006 Jul 15;4(3):115-25. doi: 10.1186/1897-4287-4-3-115. Hered Cancer Clin Pract. 2006. PMID: 20223015 Free PMC article.
-
Genetically engineered mouse models of head and neck cancers.Oncogene. 2023 Aug;42(35):2593-2609. doi: 10.1038/s41388-023-02783-7. Epub 2023 Jul 20. Oncogene. 2023. PMID: 37474617 Free PMC article. Review.
-
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25. J Clin Endocrinol Metab. 2014. PMID: 24606083 Free PMC article. Clinical Trial.
-
Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.Endocr Pathol. 2012 Jun;23(2):115-22. doi: 10.1007/s12022-012-9200-4. Endocr Pathol. 2012. PMID: 22371144 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
